The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs.The company is set to capture 50% ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination therapy might change that.

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

India's Rs 628-crore anti-obesity market sees heightened competition as Wegovy and Mounjaro post strong sales amid rising ...

Incidence of obesity and diabetes is rising in India, the world's most populous country, which also ranks among the worst ...